| cyclophosphamide / Generic mfg. |
ACTRN12622001186741: Autologous Stem Cell Transplant in Neuro-Inflammatory diseases other than multiple sclerosis |
|
|
| Not yet recruiting | N/A | 5 | | | The Alfred- Melbourne, The Alfred-Melbourne | Neuro-Inflammatory disease | | | | |
ACTRN12622001514796: KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme |
|
|
| Recruiting | N/A | 18 | | | Royal Adelaide Hospital, Neurosurgical Research Foundation | Glioblastoma Multiforme | | | | |
ACTRN12622000675729: Leveraging Chimeric Antigen Receptor-Expressing T Cells for Children with Diffuse Midline Glioma |
|
|
| Recruiting | N/A | 18 | | | Sydney Children's Hospitals Network, Levi's Project, Australian Philanthropic Services, Cancer Institute NSW, Medical Research Future Fund, Australian Government Department of Health, Cure Cancer Australia Foundation | Central Nervous System Tumour, Diffuse Midline Glioma, High Grade Glioma, Diffuse Intrinsic Pontine Glioma | | | | |
ChiCTR-ONRC-13003502: A multi-center, prospective, non-randomized clinical study of bortezomib / thalidomide, cyclophosphamide and dexamethasone combined with autologous hematopoietic stem cell transplantation in patients with de novo advanced multiple myeloma |
|
|
| Recruiting | N/A | 400 | | Chemotherapy ;Chemotherapy plus ASCT ;Chemotherapy ;Chemotherapy plus ASCT | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Self-financing | Multiple Myeloma | | | | |
ChiCTR1800014708: Clinical Study of Intensive Immunoablative conditioning regimen on Umbilical Cord Blood Transplantation Related Diseases |
|
|
| Recruiting | N/A | 30 | | Busulfan+Cyclophosphamide+Fludarabine conditioning regimen | ZhongDa Hospital Southeast University; Level of the institution：, Self-financing | malignant and nonmalignant hematological disease | | | | |
MeRCY, NCT06216990: Metastatic or Refractory Soft Tissue Sarcomas and Metronomic Cyclophosphamide: Further Assessment of Efficacy and Safety |
|
|
| Completed | N/A | 60 | NA | | Centre Hospitalier Universitaire de Besancon | Sarcoma, Soft Tissue Sarcoma | 12/21 | 07/22 | | |
| No Longer Available | N/A | | Europe | CEOP/IMVP-Dexa chemotherapy | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lymphoma | | | | |
NCT00372866: Chemotherapy and Bevacizumab in Treating Women With Invasive Breast Cancer |
|
|
| Recruiting | N/A | 30 | US | bevacizumab, filgrastim, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, adjuvant therapy | Premiere Oncology | Breast Cancer | | | | |
NCT00547196: AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders |
|
|
| Completed | N/A | 10 | US | filgrastim, Busulfan, Busilvex, Cyclophosphamide, CTX, Cyclosporine, CsA, Fludarabine phosphate, Fludara, Melphalan, Alkeran, Mycophenolate Mofetil, MMF, allogeneic hematopoietic stem cell transplantation, AlloHCT, umbilical cord blood transplantation, total-body irradiation, TBI, Fractionated total body irradiation, FTBI | City of Hope Medical Center, National Cancer Institute (NCI) | Leukemia, Lymphoma, Myelodysplastic Syndromes | 11/09 | 05/24 | | |
NCT01005537: Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US | aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Melanoma (Skin) | 10/10 | | | |
NCT00647010: T-cell Recovery in Patients With Leukemia, Advanced Lymphoma, Myelodysplastic Syndrome, or Myeloproliferative Disorder Receiving Alemtuzumab and Undergoing Donor Stem Cell Transplant |
|
|
| Recruiting | N/A | 40 | US | alemtuzumab, cyclophosphamide, cytarabine, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, total-body irradiation | Baylor College of Medicine | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms | 12/12 | | | |
ChiCTR-ONRC-12002259: The open randomized controlled multicenter clinical study of the treatment of connective tissue diseases related interstitial lung disease with cyclophosphamide and mycophenolate mofetil |
|
|
| Completed | N/A | 60 | | CYC ;MMF | Guangdong General Hospital; hospital： Guangdong General Hospital, self-financing | connective tissue diseases related interstitial lung disease | | | | |
NCT01005745: Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma |
|
|
| Active, not recruiting | N/A | 19 | US | Surgery, Tumor Infiltrating Lymphocytes (TIL), T-cell, lymphocyte, Administration of Lymphodepletion, Cytoxan, Adoptive Cell Transfer, High Dose IL-2, Interleukin-2, Aldesleukin, Proleukin | H. Lee Moffitt Cancer Center and Research Institute | Metastatic Melanoma | 01/14 | 12/24 | | |
NCT01701674: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts |
|
|
| Active, not recruiting | N/A | 13 | US | Ipilimumab, Yervoy, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Cytoxan, Fludarabine as Part of Lymphodepletion, Fludara, High Dose IL-2, Interleukin-2, Aldesleukin, Proleukin, Adoptive Cell Therapy with TIL, ACT | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Iovance Biotherapeutics, Inc. | Metastatic Melanoma | 04/16 | 12/25 | | |
| Recruiting | N/A | 40 | | Give intravenous glucocorticoid treatment for three days, the first day of 500 mg, 250 mg, 250 mg on the third day the next day, once a month, a course in April, glucocorticoid total 4000 mg ;Once a week, 500 mg, for 6 weeks, then once a week, 250 mg, for six weeks, glucocorticoid total 4500 mg ;Once a week, 500 mg, six weeks in a row, then once a week, 250 mg, six weeks in a row, add 0.2 cyclophosphamide use once a week at the same time, glucocorticoid total 4500 mg | The sencond hospital of huaian, Jiangsu; The sencond hospital of huaian, Jiangsu, self-raised | Moderate and severe thyroid related ophthalmopathy | | | | |
ChiCTR-OPN-15007180: The effect to the pharmacodynamics of muscle relaxant in breast cancer patients who received neoadjuvant chemotherapy |
|
|
| Recruiting | N/A | 240 | | none ;received four cycles of doxorubicin, 5-Fu andcyclophosphamide ;received four cycles of combined chemotherapy andtaxol chemotherapy respectively | Beijing Cancer Hospital; Beijing Cancer Hospital, none | effects of neoadjuvant chemotherapy on neuromuscular blocking agents | | | | |
ChiCTR-OPB-15007187: The effect to the pulmonary function in breast cancer patients who received neoadjuvant chemotherapy |
|
|
| Recruiting | N/A | 90 | | none ;4 cycles of doxorubicin, 5-Fu andcyclophosphamide ;4 cycles of taxol | Beijing Cancer Hospital; Beijing Cancer Hospital, scientific research funds of Beijing Cancer Hospital; 2014 research initiation funds for the returned students(supports by the Ministry of Human Resources andSocial Security) | effects of neoadjuvant chemotherapy on pulmonary function of breast cancer patients | | | | |
NCT01357733: Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients |
|
|
| Active, not recruiting | N/A | 53 | RoW | Early interim FDG PET/CT after 1 cycle of R-CHOP | The Catholic University of Korea | Lymphoma, Large B-Cell, Diffuse | 11/17 | 03/23 | | |
|
AutoChron, NCT03000296: Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease |
|
|
| Active, not recruiting | N/A | 50 | RoW | Autologous Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplatation | Beneficência Portuguesa de São Paulo | Crohn's Disease, Inflammatory Bowel Diseases, Gastroenteritis | 12/17 | 12/24 | | |
NCT03408223: Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia |
|
|
| Recruiting | N/A | 100 | RoW | total body irradiation, TBI, total marrow and lymphoid irradiation, TMLI | Affiliated Hospital to Academy of Military Medical Sciences | Acute Leukemia | 08/18 | 12/22 | | |
SPORTNATHy, NCT06190600: Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy |
|
|
| Active, not recruiting | N/A | 40 | Europe | High Intensity Interval Training (HIIT), Physical activity, neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab), chemotherapy, Standard Supportive Care | The Greater Poland Cancer Centre | Breast Cancer | 03/20 | 12/26 | | |
ChiCTR-IPR-17012144: A pilot randomized controlled trial for comparing CDA-II in Combination With DT-PDCE versus DT-PDCE Alone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 50 | | Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4; Uroacitides Injection 300ml / d, D1-D7. ;Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4 | Henan Cancer Hospital; Henan Cancer hospital, Self-financing | Relapsed or Refractory Multiple Myeloma | | | | |
ChiCTR-INR-16007755: Low-dose decitabine combined with modified busulfan/ cyclophosphamide as a conditioning regimen followed by allogeneic stem cell transplantation for the treatment of high-risk patients with acute myeloid leukaemia: a prospective randomized controlled clinical study |
|
|
| Recruiting | N/A | 90 | | decitabine combined with modified Bu/Cy conditioning regimen ;modified Bu/Cy conditioning regimen | the First Affiliated Hospital of Soochow University; the First Affiliated Hospital of Soochow University, Self-financing | acute myeloid leukemia | | | | |
ChiCTR-OPC-16008561: Etiological classification of hemophilia and study on the efficacy and safety of non-blood product medicine in treating hemophlilia treatment |
|
|
| Recruiting | N/A | 117 | | Congenital hemophilia: Using XueYou-Mixture and Promoting Hepatocyte Growth Factor (PHGF) ;Acquired hemophilia: Using non-hormonal immunity inhibitor (Thymosins, cyclophosphamide, Compound?Glycyrrhizin, Mycophenloate Mofetil Tablets) ;Using FVIII /FIX | Shaanxi Yida Hemophilia Institute affiliated Xi’an Xincheng Yida Hospital; Shaanxi Yida Hemophilia Institute affiliated Xi’an Xincheng Yida Hospital, Shaanxi Yida Hemophilia Institute fund | Hemophilia | | | | |
ChiCTR-INR-17013961: A pilot randomized controlled trial for comparing decitabine in Combination With DT-PDCE versus DT-PDCE Alone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 50 | | dexamethasone 40mg/d, po, 4d; thalidomide 100-200mg/d, D1-4; cis-platinum 10mg/m2, D1-4; liposomal doxorubicin hydrochloride 40 mg/m2, D1; cyclophosphamide 400mg/m2, D1-4; etoposide 40mg/(m2?d), D1-4; decitabine 10mg/d, D1-D5. 4 weeks/cycle, 3cycles in total ;dexamethasone 40mg/d, po, 4d; thalidomide 100-200mg/d, D1-4; cis-platinum 10mg/m2, D1-4; liposomal doxorubicin hydrochloride 40 mg/m2, D1; cyclophosphamide 400mg/m2, D1-4; etoposide 40mg/(m2?d), D1-4; 4 weeks/cycle, 3cycles in total | Henan Cancer Hospital; Henan Cancer hospital, Self-financing | Relapsed or Refractory Multiple Myeloma | | | | |
NCT06155188: Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia |
|
|
| Recruiting | N/A | 60 | RoW | applying of FLU+CY post-HSCT | Nanfang Hospital, Southern Medical University | Leukemia, Stem Cell Transplant, Cord Blood | 12/26 | 12/26 | | |
ChiCTR1800016003: Clinical observation of the first-line treatment of diffuse large B cell lymphoma with Thalidomide combined or sequential R-CHOP |
|
|
| Not yet recruiting | N/A | 80 | | Thalidomide+R-CHOP ;R-CHOP | The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, no | lymphoma | | | | |
ChiCTR2000031197: Withdraw due to unable to provide IPD for reviewing T Cell Receptor-transduced T Cells for Treatment of Patients with Malignancies |
|
|
| Recruiting | N/A | 36 | | Drug: Cyclophosphamide On days -6 through -5, Cyclophosphamide 1g/m^2/day IV will be infused over 60 minutes. Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m^2/day IV will be infused over 30 minutes. Therapy: Anti-NY ESO-1 TCR-transduced T cells Modified cells will be infused IV over 30 minutes. | Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Shenzhen Science and Technology Innovation Committee | Cancer | | | | |
ETCMSLE, ChiCTR-ONC-15007547: Clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus: a multicenter prospective cohort study |
|
|
| Recruiting | N/A | 528 | | Traditional Chinese medicine combined western medicine ;Treating by Western medicine (sugar cortical hormone, hydroxychloroquine, and methotrexate, azathioprine, or cyclophosphamide) | Zhejiang Chinese Medical University; Zhejiang Chinese Medical University, National public welfare industry special scientific research projects | systemic lupus erythematosus | | | | |
ChiCTR-IPR-17011503: A pilot randomized controlled trial evaluating pegylated liposomal doxorubicin (PLD) /cyclophosphamide (CTX) versus epirubicin/CTX as neoadjuvant therapy for operable breast cancer |
|
|
| Recruiting | N/A | 90 | | pegylated liposomal doxorubicin(PLD) 35 mg/m2 plus cyclophosphamide (CTX) 600 mg/m2, every 21 days for 4 cycles. ;epirubicin 90 mg/m2 plus cyclophosphamide (CTX) 600 mg/m2, every 21 days for 4 cycles. | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, sponsored by reserchers | Breast Cancer | | | | |
NCT03380039: Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma |
|
|
| Active, not recruiting | N/A | 6 | RoW | CAR-BCMA T cells, BCMA-redirected autologous T cells, Fludarabine, Cyclophosphamide | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, CARsgen Therapeutics Co., Ltd. | Refractory or Relapsed Multiple Myeloma | 07/20 | 07/23 | | |
NCT00950846: Umbilical Cord Blood Transplant for Congenital Pediatric Disorders |
|
|
| Completed | N/A | 40 | US | Busulfan, Busulfex, Cytoxan, Cyclophosphamide, Fludarabine, Fludera, Cord Blood Stem Cell Infusion | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine | Congenital Pediatric Disorders | 07/20 | 02/21 | | |
ChiCTR1900024706: Double-Blind Comparison of Intravenous Cyclophosphamide and Intrathecal Methotrexate Plus Dexamethasone in Neuropsychiatric Lupus Erythematosus Patients |
|
|
| Recruiting | N/A | 96 | | Intravenous Cyclophosphamide ;Intrathecal Methotrexate Plus Dexamethasone | Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine; Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Raise independently | Neuropsychiatric Lupus Erythematosus | | | | |
ChiCTR1900026462: Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cells co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia |
|
|
| Recruiting | N/A | 20 | | low dose post Cyclophosphamide and Mesenchymal stem cell | Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital; He'nan Cancer Hospital, The medication and treatment scheme of this experiment is the routine scheme of the hospital. The medication of the subjects is not free, there is no other subsidy such as transportation fee and blood | aplastic anemia，AA | | | | |
ChiCTR1900021945: A randomized cross-over controlled trial for comparing efficacy and safety of PEG-rhG-CSF versus rhG-CSF in the prevention of chemotherapy-induced neutropenia in sarcoma patients with doxorubicin + isocyclophosphamide treatment |
|
|
| Not yet recruiting | N/A | 78 | | cycle 1: PEG-rhG-CSF 100μg/kg, once; cycle 2: rhG-CSF 5μg/kg/d, daily up to ANC≥2×10^9/L ;cycle 1: rhG-CSF 5μg/kg/d, daily up to ANC≥2×10^9/L; cycle 2: PEG-rhG-CSF 100μg/kg, once. | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chinese Society of Clinical Oncology | sarcoma | | | | |
| Recruiting | N/A | 4000 | RoW | Dexamethasone continuous, Dexamethasone intermittent, Dexamethasone, Methylprednisolone, Daunorubicin, Idarubicin, Bortezomib, Second phase of induction, Standard induction therapy, Standard consolidation therapy | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Childhood Acute Lymphoblastic Leukemia | 11/20 | 11/25 | | |
ChiCTR1900027957: Efficacy and safety of multitarget therapy with cyclophosphamide and sirolimus for lupus nephritis: a single-arm, single-center pilot study |
|
|
| Recruiting | N/A | 20 | | cyclophosphamide and sirolimus | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical Universit, None | lupus nephritis | | | | |
NCT03302403: Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors |
|
|
| Active, not recruiting | N/A | 18 | RoW | CAR-CD19 T cell, CD19-redirected Autologous Cell, CAR-BCMA T cell, BCMA-redirected Autologous Cell, CAR-GPC3 T cell, GPC3-redirected Autologous Cell, CAR-CLD18 T cell, Claudin18.2-redirected Autologous Cell, Fludarabine, Cyclophosphamide | Kang YU, CARsgen Therapeutics Co., Ltd. | B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma, Pancreatic Carcinoma, Adenocarcinoma of Esophagogastric Junction | 12/20 | 12/23 | | |
NCT02916316: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell |
|
|
| Active, not recruiting | N/A | 127 | Europe | R-CHOP with doxorubicin, R-CHOP with doxorubicin analogue, R-COMP | Fondazione Italiana Linfomi - ETS | Lymphoma, Large B-Cell, Diffuse Large B-Cell | 12/20 | 12/24 | | |
ChiCTR-INR-16010071: Clinical trial of Priming with Recombinant Human Granulocyte ColonyeStimulating Factor on low dose Decitabine combined with Busulfex and Cyclophosphamide for High-Risk Acute Myeloid Leukemia Patients Undergoing Human Leukocyte Antigene Matched Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | N/A | 194 | | G-CSF 150ug qd -13d to -8d; Decitabine 20mg/m2 qd -12d to -8d, Bu 0.8mg/kg q6h d-7 to d-4, CTX 60mg/kg d-3 to d-2 ;Bu 0.8mg/kg q6h d-7 to d-4, CTX 60mg/kg d-3 to d-2 | Xinqiao Hospital, Chongqing; Xinqiao Hospital, Chongqing, Chinese National Natural Science81500147 | Acute myeloid leukemia | | | | |
ChiCTR1900023509: Allogeneic Hematopoietic Stem Cell Transplantation with Risk-adapted Conditioning Regimens for Children with Aplastic Anemia or Refractory Cytopenia of Childhood: a Single-Center Prospective Trial |
|
|
| Recruiting | N/A | 150 | | Fludarabine150 mg/m2 +Cyclophosphamide200 mg/kg+ Thymoglobuline10mg/kg ;Fludarabine200 mg/m2 +Cyclophosphamide120 mg/kg+ Thymoglobuline10mg/kg+300cGy TBI ;Fludarabine200 mg/m2 +Cyclophosphamide120 mg/kg+ Thymoglobuline10mg/kg+ Busulfan 8mg/kg | Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center | aplastic anemia，Refractory Cytopenia of Childhood | | | | |
| Recruiting | N/A | 30 | | Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate | Xiangya Hosptial of Central South University; Level of the institution：, Researchers | Aplastic Anemia | | | | |
GALENO 1, NCT04474951: Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies |
|
|
| Recruiting | N/A | 60 | Europe | Stinging Nettle, Peppermint | Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi | Breast Cancer, Gynecologic Cancer | 03/21 | 09/21 | | |
ChiCTR1800015414: Clinical Study of Intensified immunoablative Conditioning Regimen on Umbilical Cord Blood Transplantation for non-malignant diseases |
|
|
| Recruiting | N/A | 75 | | fludarabine (FLU)+ BU+cyclophosphamide (CY) | Zhongda Hospital Southeast University; Level of the institution：, Self-financing | Non-malignant diseases | | | | |
ChiCTR1800016732: A prospective randomized controlled study using comprehensive geriatric assessment to guide treatment decisions in older patients with diffuse large b-cell lymphoma |
|
|
| Not yet recruiting | N/A | 150 | | R-CHOP ;Support therapy | Beijing Hospital; Beijing Hospital, Beijing Committee of Science and Technology | diffuse large b-cell lymphoma | | | | |
NCT04385641: Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer |
|
|
| Recruiting | N/A | 18 | RoW | Cell infusion for Dose-finding (Group A), Cell infusion for Extended research (Group B) | Shandong Golden Brick Biotechnology Co., Ltd. | Advanced Gastric Cancer, Gastroesophageal Cancer | 10/21 | 10/22 | | |
| Completed | N/A | 20 | RoW | PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells, PD1-CD19-CART | Bioray Laboratories, First Affiliated Hospital of Zhejiang University | B-cell Lymphoma | 11/21 | 11/23 | | |
NCT04336501: Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation |
|
|
| Recruiting | N/A | 20 | RoW | IM19 CAR-T | Beijing Immunochina Medical Science & Technology Co., Ltd. | Leukemia | 12/21 | 12/21 | | |
NCT03594162: Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch |
|
|
| No Longer Available | N/A | | US | iC9-CAR19 cells, CAR.CD19 T cells, AP1903, Rimiducid, Cyclophosphamide, Neosar, Fludarabine, Fludara | UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals | Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders | | | | |
NCT04792593: Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 15 | RoW | Senl-h19 CAR-T, CD19 CAR-T | Hebei Senlang Biotechnology Inc., Ltd. | B-ALL | 12/21 | 02/22 | | |
NCT04796441: Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation |
|
|
| Recruiting | N/A | 20 | RoW | CAR-γδT, CD19 CAR-T | Hebei Senlang Biotechnology Inc., Ltd. | AML | 12/21 | 02/22 | | |
ChiCTR1900021070: A randomized controlled trial for Neoadjuvant Everolimus Plus EC followed by T Compared With EC followed by T in patients with ER-positive, HER2-negative operable breast cancer |
|
|
| Recruiting | N/A | 214 | | Everolimus (10 mg/ day, Po) combined with EC (famacin 90mg/m2 iv d1+ cyclophosphamide 600mg/m2 iv d1, 21 days in a cycle) 4 cycles followed by T (docetaxel 100mg/m2, iv, d1, 21 days in a cycle) 4 cycles ; EC (famacin 90mg/m2 iv d1+ cyclophosphamide 600mg/m2 iv d1, 21 days in a cycle) 4 cycles followed by T (docetaxel 100mg/m2, iv, d1, 21 days in a cycle) 4 cycles | SUN YAT-SEN MEMORIAL HOSPITAL, SYSU; SUN YAT-SEN MEMORIAL HOSPITAL, SYSU, SUN YAT-SEN MEMORIAL HOSPITAL, SYSU | Breast Cancer | | | | |
ChiCTR1800019833: Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone |
|
|
| Not yet recruiting | N/A | 60 | | Cyclophosphamide combined with hormone therapy ;Cyclophosphamide combined with hormone therapy | Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University, Natural Science Foundation of Zhejiang Province | Idiopathic Membranous Nephropathy | | | | |
ChiCTR1900028212: A multicenter, prospective, single-arm, exploratory clinical study of neoadjuvant therapy of her2-positive breast cancer with pyrotinib maleate tablets combined with paclitaxel for injection (albumin bound) |
|
|
| Recruiting | N/A | 90 | | pyrotinib maleate tablets combined with albumin paclitaxel combined with epirubicin and cyclophosphamide | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Self raise independently | breast cancer | | | | |
| Recruiting | N/A | 500 | RoW | | Interni hematologicka klinika FNKV, Charles University, Czech Republic, General University Hospital, Prague, University Hospital Olomouc, University Hospital Hradec Kralove, University Hospital, Motol | Prognostic Cancer Model | 12/23 | 12/27 | | |
NCT03638193: Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer |
|
|
| Recruiting | N/A | 10 | RoW | CART-meso cells | Shenzhen BinDeBio Ltd., The First Affiliated Hospital with Nanjing Medical University | Pancreatic Cancer | 02/22 | 02/22 | | |
| Withdrawn | N/A | 30 | NA | BAFF serum levels | Universidad de Antioquia, ARTMEDICA | Lupus Nephritis | 03/22 | 01/23 | | |
ChiCTR2100043528: Early identification and evaluation on the cardiotoxicity of cyclophosphamide in hematopoietic stem cell transplantation: based on spot tracking ultrasound imaging and miRNA |
|
|
| Recruiting | N/A | 66 | | Nil | The First Affiliated Hospital of Shandong First Medical University/Qianfoshan Hospital of Shandong Province; The First Affiliated Hospital of Shandong First Medical University, National Natural Science Foundation of China in The First Affiliated Hospital of Shandong First Medical University | cardiotoxicity of cyclophosphamide | | | | |
NCT04438603: The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy |
|
|
| Recruiting | N/A | 180 | RoW | Intervention for incipient patients at low risk of disease progression, Intervention for patients at high risk of disease progression | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, RenJi Hospital, Shanghai Zhongshan Hospital, Longhua Hospital Shanghai University of Traditional Chinese Medicine | IgA Nephropathy | 03/22 | 09/22 | | |
ChiCTR2200055471: Efficacy and safety of low-dose CTX combined with belimumab based on B/T cell balance in the treatment of moderate to severe systemic lupus erythematosus: a medical record-based study |
|
|
| Recruiting | N/A | 82 | | Low-dose cyclophosphamide combined with belimumab ;Standard dose cyclophosphamide | The Second Hospital of Shanxi Medical University; The Second Hospital of Shanxi Medical University, 2020 Shanxi Province Emerging Industry Leadership Project (2020-15) | Systemic Lupus Erythematosus (SLE) | | | | |
ChiCTR2000038297: A prospective, single center study of Modified Post-Transplantation Cyclophosphamide with Total Body Irradiation (PTCY/TBI) condition regimen for alternative donor transplantation in aplastic anemia |
|
|
| Recruiting | N/A | 100 | | Post CY with TBI conditional regimen | Guangzhou First People's Hospital; Guangzhou First People's Hospital, Guangzhou Major Clinical High-tech Projects Fund 2019 | Aplastic anema | | | | |
ChiCTR1900024299: The first-line treatment of diffuse large B-cell lymphoma with sintilimab combined R-CHOP regimen: a single-arm, single-center clinical trial |
|
|
| Recruiting | N/A | 40 | | sintilimab combined with R-CHOP regimen | The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Wu Jieping Medical Foundation | diffuse large B-cell lymphoma | | | | |
NCT04067180: Randomized Clinical Study Assessing Haplo vs. URD in AML |
|
|
| Terminated | N/A | 18 | Europe, Canada, RoW | allogeneic stem cell transplantation with a haplo-identical family donor graft, allogeneic stem cell transplantation with a matched unrelated donor graft | Karolinska Institutet, Skane University Hospital, Uppsala University Hospital, University Hospital, Linkoeping, University Hospital, Umeå, Sahlgrenska University Hospital, Sweden, Oslo University Hospital, St. Petersburg State Pavlov Medical University, Princess Margaret Hospital, Canada, Medical University of Vienna | Acute Myeloid Leukemia | 08/22 | 08/22 | | |
NCT04447573: Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 20 | RoW | BCMA CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital | Multiple Myeloma | 08/22 | 12/22 | | |
NCT04447547: Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | CD19 CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital | Non-hodgkin's Lymphoma | 08/22 | 12/22 | | |
NCT04546906: Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 20 | RoW | CD22 CAR-T | Hebei Senlang Biotechnology Inc., Ltd. | B-ALL | 09/22 | 12/22 | | |
NCT04546893: Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia |
|
|
| Recruiting | N/A | 20 | RoW | CD19 CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Ludaopei Hospital | B-ALL | 09/22 | 12/22 | | |
ChiCTR2100043079: Observational study of R2 chop (lenalidomide, rituximab, cyclophosphamide, doxorubicin, vindesine / vinorelbine and prednisone) in the first-line treatment of high-risk / high-risk DLBCL |
|
|
| Recruiting | N/A | 100 | | Lenalidomide, 25mg, orally on day 1-14 | The First Affiliated Hospital of Kunming Medical University; The First Affiliated Hospital of Kunming Medical University, manufactor | DLBCL | | | | |
NCT04568161: Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses |
|
|
| Recruiting | N/A | 15 | RoW | Physical Characteristics, Muscular Sympathetic Nervous Activity, Cardiac Function, Heart rate, Blood pressure, Blood Assessments, Muscle blood flow, Endothelium-dependent vascular function, Vascular intima-media thickness, Physical Capacity, Anthracycline & Cyclophosphamide treatment scheme | University of Sao Paulo General Hospital, Universidade Federal Fluminense, Hospital Israelita Albert Einstein | Cardiotoxicity, Cardiovascular Disease, Neurovascular Disorder, Endothelial Disfunction, Breast Cancer | 09/22 | 03/25 | | |
ChiCTR2000036709: Study on early warning of rapid progressive interstitial lung disease in dermatomyositis |
|
|
| Not yet recruiting | N/A | 30 | | Glucocorticoid + cyclophosphamide + cyclosporin ;Glucocorticoid + cyclophosphamide + Tofacitinib | Zhongshan Hospital of Fudan University; Zhongshan Hospital of Fudan University, Shanghai Shenkang Hospital development Center | Dermatomyositis | | | | |
NCT01464606: International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry |
|
|
| Active, not recruiting | N/A | 156 | US | Vincristine, Vincristine; Oncovin, Dactinomycin, Actinomycin-D, Cyclophosphamide, Cytoxan, Ifosfamide, Ifos, Doxorubicin, Adriamycin | Children's Hospitals and Clinics of Minnesota | Pleuropulmonary Blastoma | 12/22 | 12/24 | | |
NCT02464774: Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | N/A | 464 | RoW | Breast-Conserving Therapy, Mastectomy, Adjuvant Chemotherapy, Radiation Therapy | Xiaoming Xie | Breast Cancer | 12/22 | | | |
| Recruiting | N/A | 2200 | RoW | Radiotherapy:, Vincristine, Etoposide, Prednisone, Doxorubicin, Dacarbazine, Cyclophosphamide | GALIA AVRAHAMI, University of Giessen | Classical Hodgkins Lymphoma in Children and Adolescents. | 12/22 | 12/27 | | |
NCT04116697: A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan |
|
|
| Recruiting | N/A | 60 | US | Acupuncture, Aromatherapy | Englewood Hospital and Medical Center | Nausea, Vomiting, Anxiety | 12/22 | 12/23 | | |
ChiCTR2100042633: Single center, open and single arm clinical study on the safety and efficacy of r2-mtx-epoch regimen in the treatment of CD5 positive diffuse large B cell lymphoma |
|
|
| Recruiting | N/A | 30 | | Rituximab combined with lenalidomide, etoposide, methotrexate, vincristine, adriamycin, cyclophosphamide, prednisone | The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University, Self-raised funds | DLBCL | | | | |
ChiCTR2200059158: Clinical study of Icariin soft capsules for prevention of neutropenia after chemotherapy for non-Hodgkin's lymphoma |
|
|
| Not yet recruiting | N/A | 14 | | Icaritin + R-CHOP | He'nan Cancer Hospital; He'nan Cancer Hospital, Beijing Shenogen Biomedical Co., Ltd. | Neutropenia due to chemotherapy (CIN) | | | | |
NCT06373744: Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients |
|
|
| Completed | N/A | 597 | RoW | cyclophosphamide , methotrexate , vinorelbine ,capecitabine | Sun Yat-sen University | Breast Cancer | 01/24 | 01/24 | | |
COmPACt, NCT03802773: Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide ( Study) |
|
|
| Recruiting | N/A | 10 | Europe | CB transplantation, Myeloablative conditioning and post-transplant cyclophosphamide | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Cord Blood Transplantation, Hematological Malignancies | 01/23 | 12/23 | | |
ChiCTR2100042456: Modified posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched sibling mobilized peripheral-blood stem-cell transplantation |
|
|
| Recruiting | N/A | 39 | | PTCY (total 60mg / kg, + 3 days and +4 days 30mg / kg) + CSA + MMF | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, New Medicine of University of Science and Technology of China (WK9110000001) | Hematologic Malignancies | | | | |
ChiCTR2000030072: Multicenter, prospective, open-label clinical study of ICD (Ixazomib / cyclophosphamide / dexamethasone) regimen for newly diagnosed POEMS syndrome |
|
|
| Recruiting | N/A | 20 | | ICD Regimen | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Self-financing | POEMS syndrome | | | | |
APOLLO, ISRCTN11542980: Evaluating alternative treatment regimens for patients who have diffuse large B-cell lymphoma that is unsuitable for standard treatment |
|
|
| No Longer Available | N/A | 56 | United Kingdom, England, Scotland | Polivy (polatuzumab vedotin-piiq) - Roche | Clatterbridge Cancer Centre NHS Foundation Trust, Roche;Hoffman-La Roche | Diffuse large B-cell lymphoma | | | | |
ChiCTR2100043831: Efficacy and safety of haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a prospective, single arm, open lable study |
|
|
| Recruiting | N/A | 30 | | receive modified PTCY regimen | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Level of the institution：, National Nature Science Fund 81873446 | Aplastic anemia | | | | |
ChiCTR1800018713: PD-1 gene knocked out CD19/CD20/CD22/CD30-CART Treatment in Relapsed/Refractory CD19/CD20/ CD22/CD30+ Non Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 30 | | Three days after cyclophosphamide and fludarabine chemotherapy, patients were treated with a dose of 1-10 x 106 CART positive T cells per kg body weight | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, The Unicar-Therapy Bio-medicine Technology Co. ,Ltd | Non Hodgkin Lymphoma | | | | |
PROTECT-06, NCT05128617: Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the Study |
|
|
| Completed | N/A | 20 | Europe | Epirubicin-cyclophosphamide, Epirubicin-endoxan, Paclitaxel, Taxol | Institut de cancérologie Strasbourg Europe, Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire | Breast Cancer | 05/23 | 05/23 | | |
NCT04938115: Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia |
|
|
| Completed | N/A | 50 | RoW | CD7 CART | Hebei Senlang Biotechnology Inc., Ltd. | Leukemia, T Cell | 05/23 | 10/23 | | |
| Recruiting | N/A | 1200 | RoW | Corticosteroid, Steroid, Prednisone, Methylprednisone, Prednisolone, Deflazacort, Cyclophosphamide, CTX, Mycophenolate mofetil, MMF, Dipyridamole, ACE Inhibitor or Angiotensin receptor antagonist | Peking University First Hospital, Nanjing PLA General Hospital, Beijing Children's Hospital, Central South University, The Children's Hospital of Zhejiang University School of Medicine, First Affiliated Hospital, Sun Yat-Sen University, Tongji Hospital, Hunan Children's Hospital, Shanghai Children's Hospital, Nanjing Children's Hospital, Children's Hospital of Chongqing Medical University, Shandong Provincial Hospital, Fuzhou General Hospital, Second Affiliated Hospital of Wenzhou Medical University, Children's Hospital of Hebei Province, Guangzhou Women and Children's Medical Center, Jiangxi Province Children's Hospital, Guangzhou First People's Hospital, Xian Children's Hospital, Capital Institute of Pediatrics, China, The First Hospital of Jilin University, Wuhan Women and Children's Medical Center, Tianjin Children's Hospital, Chengdu Women's and Children's Central Hospital, The First People's Hospital of Yunnan | IgA Nephropathy, Proteinuria in Nephrotic Range, Immunosuppressive Treatment | 12/24 | 12/24 | | |
NCT04101578: Clinical Prognosis and Progression of Myasthenia Gravis Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg), Pyridostigmine Bromide, Prednisone, Methylprednisolone, Azathioprine, Tacrolimus, Cyclosporin A, Cyclophosphamide, Mycophenolate Mofetil, Methotrexate | Da, Yuwei, M.D. | Myasthenia Gravis | 06/23 | 12/24 | | |
NCT05389514: Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors |
|
|
| Available | N/A | | NA | Cyclophosphamide, Cytoxan, Cytoxan Lyophilized, Cy, Gemcitabine, Gemzar, Pembrolizumab, KEYTRUDA, MK-3475, Cell Infusion | Providence Health & Services | KRAS G12V Mutant Advanced Epithelial Cancers | | | | |
NCT05931042: Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review |
|
|
| Completed | N/A | 1209 | RoW | Trastuzumab | Rawalpindi Medical College | HER2+ Breast Cancer | 06/23 | 06/23 | | |
NCT04610125: Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children |
|
|
| Recruiting | N/A | 30 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Leukemia, Lymphoma | 06/23 | 06/25 | | |
NCT05667883: Prognostic Model of GC/CTX in the Treatment of MN |
|
|
| Not yet recruiting | N/A | 50 | NA | glucocorticoid + cytoxan | Qianfoshan Hospital | Idiopathic Membranous Nephropathy | 07/23 | 12/23 | | |
NCT06041893: Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide |
|
|
| Recruiting | N/A | 20 | RoW | ATG-LDPTCy | Samsung Medical Center | Haploidentical Hematopoietic Stem Cell Transplantation | 07/23 | 12/25 | | |
NCT05850845: Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN |
|
|
| Not yet recruiting | N/A | 40 | NA | Microscopic hyperspectral imaging system | Qianfoshan Hospital | Hyperspectral Imaging, Idiopathic Membranous Nephropathy, Cyclophosphamide | 07/23 | 12/23 | | |
LY-SET-HAPLO, NCT03079089: Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders |
|
|
| Active, not recruiting | N/A | 40 | Europe | Sequential Packaging (SET), Transfusion graft, Prevention of GVHD, Care supports, Lymphocyte injection of prophylactic donor (PDLI) | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | Refractory or Relapsed Lymphoid Haemopathy | 07/23 | 07/23 | | |
NCT05777369: R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | N/A | 30 | NA | Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide, Vincristine/Vindesine, Prednisone | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B-cell Lymphoma | 08/23 | 08/24 | | |
NCT01850108: Non-Myeloablative Conditioning and Bone Marrow Transplantation |
|
|
| Active, not recruiting | N/A | 26 | Europe, US | Thymoglobulin, Fludarabine, Fludara®, Cyclophosphamide (CTX), Cytoxan, Mesna, Sirolimus, rapamycin, Rapamune®, Mycophenolate mofetil (MMF), Bone marrow transplantation, Total body irradiation | Vanderbilt-Ingram Cancer Center | Sickle Cell Disease, Hemoglobinopathies | 11/23 | 12/24 | | |
| Recruiting | N/A | 64 | RoW | R-CDOP | oubai, MD/PhD | Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | 09/23 | 09/28 | | |
ChiCTR2200063705: Mechanism of aGVHD prophylaxis (PTCy vs. ATG) on T cell activation in haploidentical stem cell transplantation |
|
|
| Recruiting | N/A | 10 | | Post-transplantation Cyclophosphamide (PTCy) ;Anti-thymocyte Globulin | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, National Natural Science Foundation of China | acute graft-versus-host disease | | | | |
NCT05532111: Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial |
|
|
| Not yet recruiting | N/A | 60 | NA | Rituximab combined with tacrolimus induction + rituximab maintenance, Rituximab combined with tacrolimus induction + tacrolimus maintenance, Glucocorticoid combined with cyclophosphamide induction + maintenance | RenJi Hospital | Efficacy and Safety | 09/23 | 09/24 | | |
| Recruiting | N/A | 200 | Europe | Cyclophosphamide | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Cyclophosphamide Toxicity, Allogenic Haematopoetic Transplantation | 10/23 | 12/23 | | |
